Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Apolipoprotein E polymorphism and plasma cholesterol response to probucol.

A C Nestruck, D Bouthillier, C F Sing

    Metabolism: Clinical and Experimental
    |August 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    On the readiness of physicians for pharmacogenomics testing: an empirical assessment.

    The pharmacogenomics journal·2017
    Same author

    Placental blood flow and the risk of preterm delivery.

    Placenta·2009
    Same author

    A PCSK9 variant and familial combined hyperlipidaemia.

    Journal of medical genetics·2008
    Same author

    Variation in 5' promoter region of the APOE gene contributes to predicting ischemic heart disease (IHD) in the population at large: the Copenhagen City Heart Study.

    Annals of human genetics·2007
    Same author

    Biochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: a road to integration of complementary diagnostic tools.

    Journal of internal medicine·2007
    Same author

    The contribution of individual and pairwise combinations of SNPs in the APOA1 and APOC3 genes to interindividual HDL-C variability.

    Journal of molecular medicine (Berlin, Germany)·2006

    Apolipoprotein E (apo E) genotype influences probucol

    Area of Science:

    • Pharmacogenetics
    • Cardiovascular Medicine
    • Biochemistry

    Background:

    • Probucol is an effective cholesterol-lowering medication.
    • Individual responses to probucol vary significantly.
    • Apolipoprotein E (apo E) polymorphism is a potential factor influencing this variability.

    Purpose of the Study:

    • To investigate the role of apolipoprotein E (apo E) polymorphism in determining variable cholesterol reduction in patients treated with probucol.
    • To assess if apo E genotype impacts probucol's efficacy in hypercholesterolemia management.

    Main Methods:

    • Retrospective analysis of 89 hypercholesterolemic Type II patients treated with probucol (1 g/d).
    • Patients were phenotyped for apolipoprotein E (apo E).
    • Stratification by familial hypercholesterolemia (FH) status (FH vs. non-FH) and subtype (IIa vs. IIb).

    Related Experiment Videos

    Main Results:

    • Significant differences in cholesterol reduction (absolute and percent change) were observed between individuals with the apo E3/3 phenotype and those carrying the epsilon 4 allele.
    • Familial hypercholesterolemia (FH) patients with the epsilon 4 allele showed the greatest reduction in cholesterol levels.
    • No significant heterogeneity in response related to age or sex was found across diagnostic classes.

    Conclusions:

    • Apolipoprotein E (apo E) genotype is a significant determinant of probucol's cholesterol-lowering efficacy.
    • The epsilon 4 allele of apo E is associated with enhanced cholesterol reduction in response to probucol, particularly in FH patients.
    • These findings highlight the potential for personalized medicine approaches in managing hypercholesterolemia with probucol based on apo E genotype.